Voluntis’ Oleena Digital Application Receives FDA’s Marketing Approval to Self-Manage Cancer Symptoms

Voluntis’ Oleena Digital Application Receives FDA’s Marketing Approval to Self-Manage Cancer Symptoms

Shots:

  • The US FDA has completed its regulatory review of Oleena software which is a Class II medical device facilitating oncology-related symptoms management and remote patient monitoring
  • Oleena is embedded with clinical algorithms offerings real-time personalized insights and actionable recommendations to the patients for managing their own symptoms while monitoring remote patients will improve clinical outcomes and minimizes the burden on health systems
  • Voluntis’ Oleena is the first prescription digital therapeutic in oncology transforming the patient’s experience through their cancer journey and is based on a software platform, Theraxium Oncology which is designed to allow data analytics and remote maintenance of digital therapeutics

Click here to­ read full press release/ article | Ref: Voluntis | Image: Digital Health London